OncLive On AirTM is a podcast from OncLive® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.
September 3rd 2020
In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
August 31st 2020
Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.
August 27th 2020
In our exclusive interview, Shilpa Gupta, MD, of Cleveland Clinic, discusses the FDA approval of avelumab in metastatic urothelial carcinoma and key findings from the JAVELIN Bladder 100 study.
August 24th 2020
In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.
August 20th 2020
In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.
August 17th 2020
In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, potential adverse effects, and recommended management strategies for the agent.
August 13th 2020
In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.
August 10th 2020
In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.
August 6th 2020
In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.
August 3rd 2020
In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.
July 30th 2020
In our exclusive interview, Courtney DiNardo, MD, MSCE, discusses the role of venetoclax in acute myeloid leukemia and explains the significance of the results of the VIALE-A trial.
July 27th 2020
In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.
July 23rd 2020
In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.
July 20th 2020
In our exclusive interview, Alexander Drilon, MD provided background on use of targeted therapy in advanced non–small cell lung cancer, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.
July 16th 2020
In our exclusive interview, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.
July 13th 2020
In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.
July 9th 2020
In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.
July 6th 2020
Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.
July 2nd 2020
In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.
June 29th 2020
Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.